← Back to headlines
Heron Therapeutics Reaffirms 2026 Guidance Despite Q1 Sales Decline
Heron Therapeutics (HRTX) has reaffirmed its 2026 guidance, driven by acute care revenue growth, even as the company reported a decline in sales for the first quarter.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
